Hester Biosciences has reported a total income of Rs.62.53 crores during the period ended June 30, 2021, compared to an income of Rs 40.54 crores during the period ended June 30, 2020. The total income for the period ended March 31, 2021, was Rs 66.65 crores

The company has posted a net profit of Rs.11.01 crores for the period ended June 30, 2021, as against a net profit of Rs 5.05 crores for the period ended June 30, 2020. The net profit for the period ended March 31, 2021, stood at Rs 10.09 crores.

The company has reported EPS of Rs.12.95 for the period ended June 30, 2021, as compared to an EPS of Rs 5.94 for the period ended June 30, 2020. The EPS for the period ended March 31,2021, stood at Rs 11.87.

In a statement, the company said that the results of Q1 FY22 have been in line with the financial forecasts and the budgets. During Q1 FY22, the overall topline grew by 50%, compared to Q1 FY21 which was affected by a nationwide lockdown during the initial period of the pandemic. Overall, the sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22. Domestic sales have registered a growth of 61% in Q1 FY22. The opening up of the domestic market has resulted in a higher demand for the products. Export sales have registered a marginal de-growth of 8% in Q1 FY22. Export orders are affected due to restricted cargo movements globally.

Hester Biosciences is one of India’s leading animal healthcare companies and is the second-largest poultry vaccine manufacturer in India.  It operates through four broad verticals: Poultry vaccines, Poultry Health products, animal vaccines and animal health products.